Abir Saraswat, Sunil Dogra, Manjunath Shenoy, Shyam Verma, Seetharam K, Sunil Ghate, Anil Ganjoo, Sanjeev Aurangabadkar, Anurag Tiwari, Shital Poojary, Arun Inamdar, Imran Majid, Mukesh Girdhar, Bela Shah, Sachin Varma, Ramkumar Ramamoorthy, Dhiraj Dhoot, Hanmant Barkate
INTRODUCTION: Super bioavailable itraconazole (SB ITZ) overcomes the limitations of conventional itraconazole (CITZ) such as inter-individual variability and reduced bioavailability. It has been approved for systemic mycoses in Australia and Europe as 50mg and the United States as 65mg and in India as 50mg, 65mg, 100mg, and 130mg. However, data on the ideal dose and duration of SB ITZ treatment in managing dermatophytosis is insufficient. This consensus discusses the suitability, dosage, duration of treatment, and relevance of using SB ITZ in managing dermatophytosis in different clinical scenarios...
May 2, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology